Recherche
-
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
(Neurology. vol. 100, n° 12, pp. e1296-e1308, 2023-03-21)Article de revueLibre accès -
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 3, 2023-02-21)Article de revueLibre accès -
MRI characteristics of MOG-Ab associated disease in adults: an update
(2021)Document de travail - Pré-publicationLibre accès -
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification among Natalizumab Users in France
(JAMA Neurology. vol. 77, n° 1, pp. 94-102, 2020-01-01)Article de revueLibre accès -
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries
(2022)Document de travail - Pré-publicationLibre accès -
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
(JAMA neurology. vol. 81, n° 3, pp. 273-282, 2024-03-01)Article de revueLibre accès -
Structure-function coupling as a correlate and potential biomarker of cognitive impairment in multiple sclerosis
(Network Neuroscience. vol. 6, n° 2, pp. 339-356, 2022-06-01)Article de revueLibre accès